On April 9, 2021 Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, reported two upcoming poster presentations accepted as late breaking abstracts at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021, to be held virtually April 10-15, 2021 (Press release, Apexigen, APR 9, 2021, View Source [SID1234577808]). Details are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title of Presentation: APX601, a Potent TNFR2 Antagonist as a Novel and Promising Approach to Reverse Tumor Immune Suppression (Abstract ID LB175)
AUTHORS: Sushma Krishnan, Ryan Alvarado, George Huang, Xiaodong Yang and Erin L Filbert
PRESENTER: Erin L. Filbert, Ph.D.
Title of Presentation: Targeting SIRPα with APX701, a Novel Myeloid Checkpoint Inhibitor (Abstract ID LB177)
AUTHORS: Ryan Alvarado, Sushma Krishnan, Minu K. Srivastava, Christine Tan, George Huang, Swati Jalgaonkar, Frances R. Bahjat, Erin Filbert and Xiaodong Yang
PRESENTER: Ryan Alvarado
The posters will be available on the e-poster website from at 8:30 am EDT on April 10, 2021, through June 21, 2021.